DonAmbroseStevensMD

Oncology • Louisville, KY

Physician

Join to view full profile

Are you Dr. Stevens?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 112 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
3991 Dutchmans Ln
Suite 405
Louisville, KY 40207
Phone+1 502-899-3366

Fax+1 502-899-3455

Summary

Dr. Don Stevens, MD is an oncologist in Louisville, Kentucky. He is currently licensed to practice medicine in Kentucky, Indiana, and Maryland. He is affiliated with Norton Womens and Childrens Hospital, Baptist Health Louisville, and UofL Health - UofL Hospital.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1986 - 1988
University of Louisville School of MedicineResidency, Internal Medicine, 1983 - 1986
University of Louisville School of MedicineInternship, Transitional Year, 1982 - 1983
University of Louisville School of MedicineResidency, Internal Medicine, 1982 - 1982
University of Louisville School of MedicineClass of 1982

Certifications & Licensure

KY State Medical License 1983 - 2026
IN State Medical License 1991 - 2025
MD State Medical License 1986 - 1989
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Top MD Consumers Checkbook

Clinical Trials

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma Start of enrollment: 2010 May 01
Completed
Phase 2
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2020 Sep 03
Recruiting
Phase 2, Phase 3
Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection Start of enrollment: 2020 Aug 14
Recruiting
Phase 2
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms Start of enrollment: 2020 Dec 21
Terminated
Phase 1
A Phase 1 Study of ADI-001 in B Cell Malignancies Start of enrollment: 2021 Mar 04
Recruiting
Phase 1
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells Start of enrollment: 2022 Feb 14
Enrolling by invitation
Join now to see all

Publications & Presentations

PubMed

Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Stu...
Frederick L Locke, Javier L Munoz, Michael T Tees, Lazaros J Lekakis, Sven de Vos
Journal of Clinical Oncology. 2025-02-13
Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies.
Jan Philipp Bewersdorf, Xiaoli Mi, Bin Lu, Andrew Kuykendall, David Sallman
Leukemia. 2025-01-24
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial.
Tycel Phillips, Michael Wang, Tadeusz Robak, David Gallinson, Don Stevens
Haematologica. 2024-09-05

Press Mentions

Genetic Testing for the BRCA Gene Mutation Helped Save Her LifeJanuary 6th, 2025
Tuesday, Dec 7 2021December 7th, 2021
News Roundup: Vermont Dept. Of Health Reports 78 New COVID-19 CasesApril 22nd, 2021
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member